Lund, Sweden, September 8, 2009 - Active Biotech AB's (NASDAQ OMX Nordic: ACTI) collaboration partner Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announce information regarding the upcoming novel data to be presented at ECTRIMS (25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis) in Düsseldorf, Germany September 9-12, 2009. To read the complete press release, please see www.tevapharm.com. For further information, please contact: Tomas Leanderson, President & CEO Tel: +46 46 19 20 95 E-mail: tomas.leanderson@activebiotech.com Göran Forsberg, VP Investor Relations & Business Development Tel: +46 (0) 46 19 11 54 E-mail: goran.forsberg@activebiotech.com About Active Biotech Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit www.activebiotech.com for more information. Active Biotech AB PO Box 724, SE-220 07 Lund Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00 Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 4:15 p.m. CET on September 8, 2009.